WP
PSTX

Woodline Partners’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Woodline Partners’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-478,861
Closed -$1.37M – 1020
2024
Q3 		$1.37M Buy
+478,861
New +$1.48M 0.01% 495

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Woodline Partners's PSTX Position: Q4 2024 in Review

Woodline Partners sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q4 2024, closing a stake of 478,861 shares — an estimated $1.37M sold.

Woodline Partners first reported a position in PSTX in Q3 2024 and held it in 1 quarter. The position peaked at $1.37M in Q3 2024. 115 funds tracked by Wall St. Rank hold PSTX as of Q4 2024.

  • Woodline Partners reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Woodline Partners sold 478,861 Poseida Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $1.37M.
  • Woodline Partners first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2024 and held it in 1 quarter.
  • Woodline Partners's Poseida Therapeutics, Inc. Common Stock position peaked at $1.37M in Q3 2024.
  • 115 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q4 2024.

Based on Woodline Partners's 13F filing for Q4 2024, filed 14 Feb 2025.